Insilico Medicine (03696) saw its shares rise more than 9% during the morning trading session. At the time of writing, the stock was up 4.49%, trading at HK$61.7 with a turnover of HK$130 million. The surge follows the company's announcement on April 8 that it has nominated ISM6200, a potent and potentially best-in-class NR3C1 inhibitor, as a preclinical candidate compound (PCC). The compound is intended for the treatment of ovarian cancer, Cushing's syndrome, and other conditions related to elevated cortisol levels, including glucocorticoid-related obesity. Public information indicates that ISM6200 is a potent and selective NR3C1 antagonist developed using Insilico Medicine's Pharma.AI platform. It exhibits a low risk of drug-drug interactions (DDI), demonstrates superior efficacy in multiple animal disease models, and possesses favorable ADME/PK properties. The compound is predicted to have a low effective dose in humans, indicating best-in-class potential. Notably, Insilico Medicine announced in late March a collaboration and license agreement with Eli Lilly, valued at up to approximately $2.75 billion, which includes an upfront payment of $115 million. The agreement covers not only the licensing of a preclinical pipeline but also multiple drug discovery collaborations on selected targets, supported by Insilico's Pharma.AI platform. Pharma.AI is a commercial generative artificial intelligence and automation platform developed by Insilico Medicine, designed to enhance the quality and efficiency of pharmaceutical research and development.
Comments